Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodney Sinclair

Showing results (221-230 of 256) with videos related to

Pageof 26
Sort By:
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|March 19, 2019
Platelet-Rich Plasma as a Treatment for Androgenetic AlopeciaAditya K Gupta, John Cole, David P Deutsch, et al.
The New England Journal of Medicine|March 25, 2022
Two Phase 3 Trials of Baricitinib for Alopecia AreataBrett King, Manabu Ohyama, Ohsang Kwon, et al.
Journal of the American Academy of Dermatology|October 18, 2024
Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trialMelissa Piliang, Charles Lynde, Brett King, et al.
Lancet (London, England)|July 27, 2020
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialEric L Simpson, Rodney Sinclair, Seth Forman, et al.
Immunotherapy|July 5, 2023
A plain language summary on ritlecitinib treatment for adults and adolescents with alopecia areataBrett King, Xingqi Zhang, Walter Gubelin Harcha, et al.
Lancet (London, England)|April 16, 2023
Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trialBrett King, Xingqi Zhang, Walter Gubelin Harcha, et al.
The Journal of Dermatology|September 27, 2024
Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalisNatasha Mesinkovska, Brett King, Xingqi Zhang, et al.
International Journal of Dermatology|February 12, 2016
Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trialsBruce Strober, Bárður Sigurgeirsson, Georg Popp, et al.
Journal of the American Academy of Dermatology|April 5, 2023
A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areataCheng Zhou, Xiumin Yang, Bin Yang, et al.
Clinical and Experimental Dermatology|October 9, 2025
A multicentre cohort study of the clinicopathological features and treatment outcomes of fibrosing alopecia in a pattern distributionGia Toan Tang, Daranporn Triwongwaranat, Marcelo de Souza Teixeira, et al.
Pageof 26

Showing results (221-230 of 256) with videos related to

Sort By:
Pageof 26
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|March 19, 2019
Platelet-Rich Plasma as a Treatment for Androgenetic AlopeciaAditya K Gupta, John Cole, David P Deutsch, et al.
The New England Journal of Medicine|March 25, 2022
Two Phase 3 Trials of Baricitinib for Alopecia AreataBrett King, Manabu Ohyama, Ohsang Kwon, et al.
Journal of the American Academy of Dermatology|October 18, 2024
Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trialMelissa Piliang, Charles Lynde, Brett King, et al.
Lancet (London, England)|July 27, 2020
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialEric L Simpson, Rodney Sinclair, Seth Forman, et al.
Immunotherapy|July 5, 2023
A plain language summary on ritlecitinib treatment for adults and adolescents with alopecia areataBrett King, Xingqi Zhang, Walter Gubelin Harcha, et al.
Lancet (London, England)|April 16, 2023
Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trialBrett King, Xingqi Zhang, Walter Gubelin Harcha, et al.
The Journal of Dermatology|September 27, 2024
Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalisNatasha Mesinkovska, Brett King, Xingqi Zhang, et al.
International Journal of Dermatology|February 12, 2016
Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trialsBruce Strober, Bárður Sigurgeirsson, Georg Popp, et al.
Journal of the American Academy of Dermatology|April 5, 2023
A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areataCheng Zhou, Xiumin Yang, Bin Yang, et al.
Clinical and Experimental Dermatology|October 9, 2025
A multicentre cohort study of the clinicopathological features and treatment outcomes of fibrosing alopecia in a pattern distributionGia Toan Tang, Daranporn Triwongwaranat, Marcelo de Souza Teixeira, et al.
Pageof 26